Solid pseudopapillary tumors of the pancreas are rare and typically occur in young women. Compared with pancreatic adenocarcinoma, solid pseudopapillary tumors are characterized by notable indolent biological behavior associated with a favorable prognosis. Despite their large size, these tumors rarely metastasize. Even in cases of hepatic metastasis, most lesions are usually solitary in distribution and are amenable to resection. We report a case of a 55-year-old man with a small solid pseudopapillary tumor (≤3-cm diameter) mimicking a pancreatic adenocarcinoma, with multiple hepatic metastases. The diagnosis was confirmed by endoscopic ultrasoundguided fine-needle biopsy using a 22-G core needle. Unfortunately, rapid tumor progression led to patient mortality 5 months after diagnosis. To our knowledge, this is the first case report that describes a small solid pseudopapillary tumor of the pancreas with multiple hepatic metastasis and poor prognosis in a patient who was diagnosed with this condition at the time of initial diagnosis. Clin Endosc
InTrodUcTIon
A solid pseudopapillary tumor (SPT) of the pancreas is a rare tumor of low malignant potential, accounting for only 1%-3% of pancreatic neoplasms. 1 SPTs commonly occur in young women and rarely metastasize, and the 5-year survival rate is estimated to be approximately 95%-97%. 2 A few SPTs show markedly aggressive behavior indicated by a tumor grade ≥T3, perineural and vascular invasion, and lymph node or distant metastasis. However, to date, no report has described a small SPT (<3-cm diameter) associated with multiple hepatic metastases identified in a male patient at the time of initial diagnosis. Interestingly, tumor progression in our patient was relatively rapid in contrast to the indolent tumor behavior that commonly characterizes SPTs.
cASe rePorT
A 55-year-old man without any underlying disease was admitted to our hospital for evaluation of a small pancreatic mass and multiple hepatic lesions, which were incidentally detected during ultrasonography. He was asymptomatic and denied a history of smoking or heavy alcohol consumption. Laboratory investigations revealed his hepatic parameters and tumor markers were within normal limits. Abdomen computed tomography (CT) revealed a 2.5-cm low attenuating mass in the pancreatic head and a less-enhancing lesion in the hepatic lobe (Fig. 1A, B) . Magnetic resonance imaging, using axial dynamic fat-saturated T1-weighted images obtained in the arterial, portal, and delayed phases, showed an ill-defined mass, 2.5 cm in diameter, with persistent delayed enhancement in the pancreatic head along with multiple low-intensity signals in both hepatic lobes (Fig. 1C, D) without any evidence of biliary and/or pancreatic duct dilatation or pancreatic parenchymal atrophy. Endoscopic ultrasound (EUS) examination revealed a mass of ill-defined mixed echogenicity, measuring approximately 2.6 cm, with calcifications in the pancreatic head and multiple irregular margins with low, dense lesions in both hepatic lobes (Fig. 1E, F Ki-67 expression rate was 8%. Based on the findings of histopathological and radiological examination, the patient was diagnosed with a pancreatic SPT with multiple hepatic metastases. Unfortunately, the patient refused any other treatment and died 5 months later, secondary to tumor progression (Fig. 3) .
dIScUSSIon
SPTs of the pancreas are rare tumors with low malignant potential that show good prognosis after complete resection. Previous studies have reported a male:female ratio of 1:9.5, with a median age of 21.97 years and a mean tumor diameter of 6.08 cm.
3 SPTs typically occur in young women and present as large tumors. Notably, <10% of patients with SPTs reported in the literature were men, with these lesions presenting a diagnostic challenge in those cases. Moreover, men with SPT tend to show late-onset disease and greater tumor aggressiveness than women. 4 The typical CT and magnetic resonance imaging features of SPT include a large well-encapculated mass with a mixture of solid and cystic components accompanied by hemorrhage. The EUS findings of SPT show a well-defined homogenous, hypoechic mass with a hyperechic rim. In the present case, there was no surrounding capsule or cystic component with hemorrhage unlike typical SPT. Reportedly, small SPTs (<3-cm diameter) present as exclusively solid lesions without cystic components and calcification. 5 Therefore, small SPTs may mimic pancreatic ductal adenocarcinoma (PDAC), although several radiological features of SPTs distinguish them from PDAC. 5 Small SPTs show no upstream pancreatic duct dila- (Table 1) . 1, [6] [7] [8] [9] [10] [11] In consideration of the high female predilection of SPTs, the occurrence of this tumor in our patient was unusual; therefore, it was not initially considered in the differential diagnosis in this case. Accurate preoperative diagnosis of an SPT is challenging. Reportedly, EUS-FNB using a core needle is a useful radiological diagnostic modality to evaluate indeterminate pancreatic lesions. 12 Acquisition of core biopsy specimens followed by IHC staining and evaluation of the preserved tissue architecture may aid in diagnosis, as observed in our patient. Currently, most SPTs are diagnosed based on their gross and microscopic appearance. IHC staining is a useful technique for SPTs that are difficult to diagnose morphologically. With regards to IHC assays, positive results with the beta-catenin stain and negative results with neuroendocrine markers, such as chromogranin A or synaptophysin, are important indicators that distinguish SPTs from pancreatic neuroendocrine tumors. 13 SPTs typically show indolent behavior and are associated with long survival rates (even in patients with disseminated disease) secondary to slow tumor doubling time (765 days). 14 Unfortunately, rapid tumor progression led to our patient's mortality 5 months after being diagnosed with this tumor. Aggressive behavior of SPTs may be attributed to the relatively high Ki-67 index observed in histopathological examination. Several studies focusing on cell cycle analysis have reported the utility of Ki-67 expression as a cell proliferation marker in many different types of cancer. The percentage of tumor cells that show positive Ki-67 expression (determined by IHC analysis) is associated with patient outcomes, and a high Ki-67 index is usually associated with poor prognosis in patients with lung, bladder, breast, and cervical cancer; and lymphoma. 15 The Ki-67 expression rate was 8% in our patient. There is a lack of consensus regarding the utility of the Ki-67 index as a prognostic marker for SPT; however, Yang et al. 16 reported that a Ki-67 index >4% may indicate poor prognosis in patients with SPT. Surgery is the treatment of choice for SPTs, and metastasectomy should also be considered if possible. 10, 17 In patients with unresectable SPT, there is no consensus on treatment. Maffuz et al. reported an unresectable SPT treated effectively by surgical resection after preoperative chemotherapy with fluorouracil and radiation. 18 Morikawa et al. showed the efficacy of paclitaxel chemotherapy in a patient with recurrent liver and lymph node metastasis, 3 months after primary SPT resection. 19 However, several studies did not show any benefits of chemotherapy in patients with unresectable SPT. [18] [19] [20] Therefore, the role of chemotherapy and/or radiotherapy in adjuvant, neo-adjuvant, or metastatic settings has not been conclusively established. 19 Surgery was contraindicated in our patient owing to multiple metastases in both hepatic lobes. Chemotherapy was considered an alternative treatment strategy; however, the patient refused all treatment. According to our experience, when clinicians encounter patients with a small pancreatic mass and multiple hepatic lesions without pancreatic duct dilatation or parenchymal atrophy, a high index of suspicion of SPT should be considered during the differential diagnosis, regardless of gender. EUS-FNB should be considered as a diagnostic modality for the evaluation of unusual pancreatic masses.
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